Compare predictions ACOR vs CRON
Loading...
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACOR’s FA Score shows that 1 FA rating(s) are green whileCRON’s FA Score has 1 green FA rating(s).
- ACOR’s FA Score: 1 green, 4 red.
- CRON’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRON’s TA Score shows that 4 TA indicator(s) are bullish.
- CRON’s TA Score: 4 bullish, 5 bearish.
Price Growth
ACOR (@Pharmaceuticals: Other) experienced а -35.20% price change this week, while CRON (@Pharmaceuticals: Other) price change was -7.28% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +9.50%. For the same industry, the average monthly price growth was +28.41%, and the average quarterly price growth was +18796.21%.
Reported Earning Dates
ACOR is expected to report earnings on Aug 08, 2023.
CRON is expected to report earnings on Aug 08, 2024.
Industries' Descriptions
@Pharmaceuticals: Other (+9.50% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ACOR | CRON | ACOR / CRON | |
| Capitalization | 16.4M | 1.01B | 2% |
| EBITDA | 44.1M | -71.8M | -61% |
| Gain YTD | -95.620 | 15.789 | -606% |
| P/E Ratio | 5.16 | N/A | - |
| Revenue | 111M | 87.2M | 127% |
| Total Cash | 32.5M | 862M | 4% |
| Total Debt | 186M | 2.55M | 7,286% |
ACOR | CRON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 92 | |
PRICE GROWTH RATING 1..100 | 50 | 40 | |
P/E GROWTH RATING 1..100 | 9 | 1 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACOR's Valuation (49) in the Biotechnology industry is in the same range as CRON (71) in the Pharmaceuticals Other industry. This means that ACOR’s stock grew similarly to CRON’s over the last 12 months.
ACOR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that ACOR’s stock grew similarly to CRON’s over the last 12 months.
CRON's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as ACOR (95) in the Biotechnology industry. This means that CRON’s stock grew similarly to ACOR’s over the last 12 months.
CRON's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as ACOR (50) in the Biotechnology industry. This means that CRON’s stock grew similarly to ACOR’s over the last 12 months.
CRON's P/E Growth Rating (1) in the Pharmaceuticals Other industry is in the same range as ACOR (9) in the Biotechnology industry. This means that CRON’s stock grew similarly to ACOR’s over the last 12 months.
| CRON | |
|---|---|
| RSI ODDS (%) | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 78% |
| Advances ODDS (%) | 23 days ago 73% |
| Declines ODDS (%) | 4 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 80% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSRLX | 12.49 | -0.01 | -0.08% |
| Goldman Sachs Rising Dividend Gr Instl | |||
| AELSX | 7.28 | -0.02 | -0.27% |
| abrdn Focused U.S. Small Cap Eq InstlSvc | |||
| TRLCX | 20.85 | -0.07 | -0.33% |
| TIAA-CREF Large-Cap Value Retire | |||
| CSMDX | 15.05 | -0.09 | -0.59% |
| Copeland SMID Cap Dividend Growth I | |||
| GSCKX | 14.00 | -0.17 | -1.20% |
| Goldman Sachs International Eq Inc C | |||